Athersys Inc (ATHXQ)

[goupupup]

Eric Jenkins, senior medical director and head of clinical operations at Athersys, says one of the advantages of MAPCs over MSCs is that they can be multiplied in much greater volume in the lab. This provides a level of consistency that will help win regulatory approval. “Being able to create millions of doses from a single donor collection permits you to develop a really well characterised, standardised and stable product on a commercial scale,” he says. “Having to frequently collect and culture bone marrow is problematic, because essentially it is a new product every time.”

https://www.reddit.com/r/ATHX/comments/iszmis/researchers_gain_head_start_in_coronavirus/?utm_source=share&utm_medium=mweb